Prospective Evaluation of Low-Dose Ketoconazole Plus Hydrocortisone (HC) in Docetaxel Pre-treated Castration-Resistant Prostate Cancer (CRPC) Patients

BACKGROUND: Ketoconazole is a well-known CYP-17-targeted systemic treatment for castration-resistant prostate cancer (CRPC). However, most of the published data has been in the pre-chemotherapy setting; its efficacy in the post-chemotherapy setting has not been as widely described. Chemotherapy-naïv...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Prostate Cancer Prostatic Dis
Main Authors: Lo, Ernest N., Beckett, Laurel A., Pan, Chong-Xian, Robles, Daniel, Suga, Jennifer M., Sands, Jacob M., Lara, Primo N.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4430382/
https://ncbi.nlm.nih.gov/pubmed/25667107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/pcan.2015.2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares